Caprotec Bioanalytics (Germany) a commercial-stage biopharmaceutical company focused on a capture compound mass spectrometry technology based on multifunctional small molecules used to target, capture, and isolate proteins, closed a $1.4M Series B financing, bringing the total round to $7.2M. Participants include LBBW Venture Capital, Creathor Venture, IBB Beteiligungsgesellschaft and ERP Startfonds.

Caprotec Bioanalytics (Germany) a commercial-stage biopharmaceutical focused on capture compounds for use in mass spec for the analysis of small molecule protein interactions, closed a $1.4M Series B financing, bringing the total round to $7.2M. Participants include LBBW Venture Capital, Creathor Venture, IBB Beteiligungsgesellschaft and ERP Startfonds.

Polyplus-Transfection (France) a commercial-stage nucleic acid reagent company, closed a $3.5M Series B financing. Participants include Alsace Inter Regio Fonds d’Investissement, Sudinnova, CIC Vizille Capital Innovation and CIC Finance.

Horizon Discovery (Unite Kingdom) a commercial-stage biological tools and services company focused on population stratification and personalized medicine, closed a $9.9M Series C financing. Participants include DFJ Esprit.

Swift Biosciences (Ann Arbor, MI) a development-stage company focused on molecular biology reagents for R&D and diagnostics, closed a $3M Series A financing. Participants include DFJ Mercury.

Stemgent (Cambridge, MA) a commercial-stage supplier of stemcell related reagents and tools, closed a $5.6M Series B financing. Participants include HealthCare Ventures and Morgenthaler Ventures.

OriGene Technologies (Rockville, MD) a commercial-stage gene-based reagent product company focused on cDNA and shRNA clone collections, purified human proteins, monoclonal antibodies, human tissues, multiplex assay products, antigen standards and IHC slides, closed a $16M Series B financing. Participants include IDG-Accel, SBI Ven Capital, TH Venture Capital Enterprise, Zero2IPO, Morningside and President International Development Corp..

Stemgent (Cambridge, MA) a commercial-stage supplier of stemcell related reagents and tools, closed a $14M Series A financing. Participants include HealthCare Ventures and Morgenthaler Ventures.

China Diagnostics Medical (International) a diagnostics company specializing on development, manufacturing and distribution of in vitro diagnostic reagents and instruments, closed a $16.5 Series B financing. Participants include China Healthcare Partnership, WI Harper, Siemens Venture Capital and Softbank China Venture Capital.

Promosome (NY, NY) an early-stage platform reagents and diagnostics biotechnology company closed a $9.6M Series B financing. Participants NGN.

BAC (Netherlands) early-stage company focused on developing purification ligands and immobilized purification products, closed a $1.9M Series B financing. Participants include Unilever Ventures, FF&P Private Equity, Fleming Family & Partners.

ForteBio (Menlo Park, CA) supplier of label-free technology for the development of life science and pharmaceutical products, closed a $25M Series C financing. Participants include OrbiMed Advisors, MPM Capital, Alloy Ventures, Latterell Venture Partners, The Vertical Group and Versant Ventures.

HandyLab (Ann Arbor, MI) commercial-stage developer of nucleic acid testing devices, closed a $19.2M Series D financing. Participants include Dow Ventures, Lurie Investments, EDF Ventures, Ardesta, Arboretum Ventures and Pfizer Strategic Investments.